跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/ISRCTN16783472
ISRCTN16783472已完成1 期

A phase Ib study to assess the safety and tolerability of oral ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MP

The University of Birmingham (UK)0 个研究点目标入组 58 人开始时间: 2015年3月19日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
58
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • •Current participant inclusion criteria as of 01/08/2018:
  • •For the Interventional component:
  • •1. Age = 16 years old
  • •2. A prior diagnosis of Essential Thrombocythaemia (ET), Polycythaemia Vera (PV) or Myelofibrosis (MF) with one of the following:
  • •2.1. = 10% blasts in blood or bone marrow with or without dysplastic changes (MPN-AP) at baseline
  • •2.2. = 20% blasts in blood or bone marrow (MPN-BP) at baseline
  • •3. In need of treatment in the opinion of the investigator
  • •4. Eastern Cooperative Oncology Group (ECOG) performance status 0-3
  • •5. Adequate liver and renal function, defined as:
  • •5.1. Liver transaminases = 3 × ULN (AST/SGOT and ALT/SGPT)
  • •5.2. Bilirubin <4 x ULN (Patients with elevated bilirubin due to Gilbert’s syndrome are eligible)
  • •5.3. GFR = 40 ml/min
  • •6. Willingness to undergo and ability to tolerate assessments during the study including bone marrow assessments and symptom assessments using patient reported outcome instruments
  • •7. Able to give valid informed consent
  • •For the Observational Component
  • •1. Age = 16 years old
  • •2. A prior diagnosis of ET, PV or MF with one of the following:
  • •2.1. Blasts in blood or marrow 10-19%
  • •with or without dysplastic changes (MPN-AP)
  • •2.2 = 20% Blasts (MPN-BP)
  • •2.3. Patients who are unwilling/unable to enter the interventional component and/or fail the interventional component entry criteria. This can include patients entered into studies with more aggressive therapy such as AML 17/19 as well as those receiving palliation only
  • •Previous participant inclusion criteria:
  • •For the Interventional component:
  • •1. Age = 16 years old
  • •2. A prior diagnosis of Essential Thrombocythaemia (ET), Polycythaemia Vera (PV) or Myelofibrosis (MF) with one of the following:
  • •2.1. Blasts in blood or marrow 10-19%
  • •with or without dysplastic changes (MPN-AP)
  • •2.2. = 20% Blasts (MPN-BP)
  • •3. In need of treatment in the opinion of the investigator
  • •4. Eastern Cooperative Oncology Group (ECOG) performance status 0-3
  • •5. Platelet or red blood cell transfusion-dependent
  • •6. Adequate liver and renal function, defined as:
  • •6.1. Liver transaminases = 3 × ULN (AST/SGOT and ALT/SGPT)
  • •6.2. Bilirubin <4 x ULN (Patients with elevated bilirubin due to Gilbert’s syndrome are eligible)
  • •6.3. GFR = 40 ml/min
  • •7. Willingness to undergo and ability to tolerate assessments during the study including bone marrow assessments and symptom assessments using patient reported outcome instruments
  • •8. Able to give valid informed consent
  • •For the Observational Component
  • •1. Age = 16 years old
  • •2. A prior diagnosis of ET, PV or MF with one of the following:
  • •2.1. Blasts in blood or marrow 10-19%
  • •with or without dysplastic changes (MPN-AP)
  • •2.2 = 20% Blasts (MPN-BP)
  • •2.3. Patients who are unwilling/unable to enter the interventional component and/or fail the interventional component entry criteria. This can include patients entered into studies with more aggressive therapy such as AML 17/19 as well as those receiving palliation only

排除标准

  • •Current participant exclusion criteria as of 01/08/2018:
  • •For the Interventional Component:
  • •1. Any co-morbidity that could limit compliance with the trial or any other condition (including laboratory abnormalities) that in the Investigators opinion will affect the patient’s participation in this trial
  • •2.New York Heart Association Class II, III, or IV congestive heart failure
  • •3. On-going cardiac dysrhythmias of grade 3, QTc prolongation >480 ms, or other factors that increase the risk of QT interval prolongation (e.g. heart failure, hypokalemia defined as serum potassium <3.0 mEq/L, family history of long QT interval syndrome)
  • •4. Erythropoietic agent within 28 days prior to registration
  • •5. Thrombopoietic agent within 14 days prior to registration
  • •6. CYP3A4 inhibitor within 7 days prior to registration
  • •7. Experimental treatment for AML or MPN within 14 days prior to registration (except Ruxolitinib and Hydroxycarbamide which can be taken up until study entry at the prestudy dose. Hydroxycarbamide must be stopped before the first scheduled day of treatment)
  • •8. Previously received 5-azacitidine
  • •9. Known contraindications to receiving azacitidine or ruxolitinib
  • •10. Known HIV seropositivity
  • •11. Known to have active hepatitis A, B, or C
  • •12. Women who are pregnant or lactating. Patients of childbearing potential must have a negative pregnancy test prior to study entry
  • •13. Patients and partners of childbearing potential not willing to use effective contraception for the duration of the study treatment and for three months after the last dose.
  • •14. Active infection = grade 3 (CTCAE criteria) at trial entry
  • •For the Observational Component:
  • •No Exclusions planned.
  • •Previous participant exclusion criteria:
  • •For the Interventional Component:
  • •1. Any co-morbidity that could limit compliance with the trial or any other condition (including laboratory abnormalities) that in the Investigators opinion will affect the patient’s participation in this trial
  • •2.New York Heart Association Class II, III, or IV congestive heart failure
  • •3. On-going cardiac dysrhythmias of grade 3, QTc prolongation >480 ms, or other factors that increase the risk of QT interval prolongation (e.g. heart failure, hypokalemia defined as serum potassium <3.0 mEq/L, family history of long QT interval syndrome)
  • •4. Erythropoietic agent within 28 days prior to registration
  • •5. Thrombopoietic agent within 14 days prior to registration
  • •6. CYP3A4 inhibitor within 7 days prior to registration
  • •7. Experimental treatment for AML or MPN within 14 days prior to registration (except Ruxolitinib and Hydroxycarbamide which can be taken up until study entry at the prestudy dose. Hydroxycarbamide must be stopped before the first scheduled day of treatment)
  • •8. Previously received 5-azacitidine
  • •9. Known contraindications to receiving azacitidine or ruxolitinib
  • •10. Known HIV seropositivity
  • •11. Known to have active hepatitis A, B, or C
  • •12. Women who are pregnant or lactating. Patients of childbearing potential must have a negative pregnancy test prior to study entry
  • •13. Patients and partners of childbearing potential not willing to use effective contraception for the duration of the study treatment and for three months after the last dose.
  • •For the Observational Component:
  • •No Exclusions planned.

研究者

发起方
The University of Birmingham (UK)

相似试验

进行中（未招募）
1 期
A clinical study to investigate safety, tolerability and dose of orally inhaled multiple doses of POL6014 in patients with Cystic FibrosisCystic Fibrosis
EUCTR2018-002550-71-DESanthera Pharmaceuticals (Switzerland) Ltd32
进行中（未招募）
1 期
A clinical study to investigate safety, tolerability and dose of orally inhaled multiple doses of POL6014 in patients with Cystic FibrosisCystic fibrosis
EUCTR2016-005110-22-DESanthera Pharmaceuticals (Switzerland) Ltd40
招募中
不适用
A phase Ib study to investigate the safety and pharmacokinetics of BR-003 in patients undergoing spinal fusion surgery
NL-OMON53887SentryX6
撤回
1 期
A phase I study of Dz13 drug targeting the c-Jun gene in subjects with melanoma skin cancerin-transit or satellite melanomaCancer - Malignant melanoma
ACTRN12613000302752The University of New South Wales38
进行中（未招募）
不适用
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome.Adult patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).MedDRA version: 17.0Level: LLTClassification code 10024348Term: Leukemia myelogenousSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10028533Term: Myelodysplastic syndromeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2013-001570-14-DEF. Hoffmann-La Roche Ltd.60
Assessing the safety and tolerability of oral... | 临床试验